Joint Formulary & PAD

Clonidine hydrochloride - Menopausal disorders

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Clonidine hydrochloride
Indication :
Menopausal disorders
Group Name :
Keywords :
Menopause, hot sweats, hot flushes, menopausal symptoms, flushing, vasomotor symptoms
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Other Indications

Below are listed other indications that Clonidine hydrochloride is used to treat.

Committee Recommendations (2)

The APC approved a change in Traffic Light Status from Blue to Green while reviewing drugs for inclusion on the Surrey Heartlands Joint Formulary.

It was agreed that GPs would initiate non-hormonal treatments for menopausal symptoms in accordance with CKS guidelines and NICE NG23: Menopause: identification and management

The Surrey & North West Sussex Area Prescribing Committee updated their recommendations in line with NICE guidance NG23 Menopause diagnosis and management in May 2020.

Clonidine is recommended for menopausal symptoms and a BLUE (with no information sheet) traffic light status has been agreed. Please refer to the Menopause -NG23 briefing paper attached below for further information (Page 13/14). SNRIs should not be routinely offered as a first line treatment for vasomotor symptoms. Clonidine is the only non-hormonal drug with a licenced indication for control of hot flushes in the UK.